Last reviewed · How we verify
MUTAGRIP
Mutagrip, developed by the University of Witwatersrand, is a marketed small molecule with an undisclosed mechanism of action, currently holding a niche position in its therapeutic area. The drug's key strength lies in its unique biological interaction, which differentiates it from other treatments despite the unknown mechanism. A primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | MUTAGRIP |
|---|---|
| Sponsor | University of Witwatersrand, South Africa |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy Safety Study of Flu Vaccine in Immunodepression Patients (PHASE3)
- Immunogenicity and Safety of the Seasonal Flu Vaccine in Elderly and in SOT Recipients (PHASE1,PHASE2)
- Imiquimod and Influenza Vaccine for Immunocompromised Patients (PHASE2)
- Efficacy of Influenza Vaccine in HIV Infected Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MUTAGRIP CI brief — competitive landscape report
- MUTAGRIP updates RSS · CI watch RSS
- University of Witwatersrand, South Africa portfolio CI